Jon S. Zawistowski

This study shows that daraxonrasib, a pan-RAS(on) inhibitor, effectively inhibits TNBC cell proliferation and tumor growth, either alone or in combination with a MEK inhibitor.

This study shows trametinib causes mitochondrial injury and innate immune activation in mouse hearts, leading to cardiomyopathy and heart failure.

This study uses ResolveOME to analyze genomic and transcriptomic data in individual cells, revealing mutations and gene expression changes linked to drug resistance and oncogenic mechanisms.